FibroGen, Inc. FGEN
9.07 USD 0.00 (+0.00%)
Jan 12, 2026, 9:30 AM EST
9.02 Day range 9.21
52-week range unavailable
- YTD
- +3.30%
- 1 year
- -41.90%
News
globenewswire.com Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16…
globenewswire.com Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the data on anti-tumor activity of FG-3246 in combination with…
defenseworld.net FibroGen (NASDAQ:FGEN) Stock Crosses Above Fifty Day Moving Average – Here’s Why FibroGen, Inc (NASDAQ: FGEN - Get Free Report) shares crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $8.96 and traded as high as $9.75.…
globenewswire.com FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it is rebranding the company to Kyntra Bio, representing the next step of the transformation of the…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
seekingalpha.com FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript FibroGen, Inc. ( FGEN ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Thane Wettig - CEO & Director David DeLucia - Senior VP & CFO Conference Call Participants Gaia…
zacks.com FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates FibroGen (FGEN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimate of a loss of $4.01. This compares to a loss of $4.25 per share a year ago.
globenewswire.com FibroGen to Report Third Quarter 2025 Financial Results SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct…
globenewswire.com FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential…
globenewswire.com FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment…
globenewswire.com FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
seekingalpha.com FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript FibroGen, Inc. (NASDAQ:FGEN ) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Company Participants Carol Gaddum - Corporate Participant Product Team Lead - Corporate Participant David…
zacks.com FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates FibroGen (FGEN) came out with a quarterly loss of $3.38 per share versus the Zacks Consensus Estimate of a loss of $2.25. This compares to a loss of $4 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
globenewswire.com FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2025 and provided an update on the company's recent developments.
benzinga.com Earnings Scheduled For August 11, 2025 
globenewswire.com FibroGen to Report Second Quarter 2025 Financial Results SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling more than 500 points on Friday.
benzinga.com Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket 
globenewswire.com FibroGen Announces 1-for-25 Reverse Stock Split SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock…
globenewswire.com FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
seekingalpha.com FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript FibroGen, Inc. (NASDAQ:FGEN ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - Chief Executive Officer David DeLucia -…
zacks.com FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.33 per share a year ago.
globenewswire.com FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2025 and provided an update on the company's recent developments.
benzinga.com Earnings Scheduled For May 12, 2025 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For March 17, 2025 - benzinga.com Earnings Scheduled For November 12, 2024
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - benzinga.com Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
- benzinga.com Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly…- benzinga.com Earnings Scheduled For February 26, 2024 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
- benzinga.com Earnings Scheduled For November 6, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 169 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 283 companies set new 52-week lows.
- benzinga.com Why REX American Resources Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 89.5% to $2.7852 after the company reported outcomes from a UroShield study conducted at the University of Southampton in the U.K.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 155 companies set new 52-week lows.